| INTRODUCTION
International data suggest that the incidence of paediatric Crohn disease (CD) is increasing while that of ulcerative colitis (UC) remains stable. [1] [2] [3] [4] [5] [6] [7] The incidence of paediatric inflammatory bowel disease in
Ireland has increased significantly since 2000. 8 Although the majority of children with paediatric inflammatory bowel disease are diagnosed in their second decade, 20%-34% present before 10 years of age. 4, [8] [9] [10] [11] [12] [13] Despite the recognised clinical and epidemiological disparities between those diagnosed before and after 10 years of age, most existing studies have treated paediatric inflammatory bowel disease as a single cohort. The Paris Classification defines early onset paediatric inflammatory bowel disease (EO-IBD) as disease diagnosed before 10 years of age (A1a). Disease diagnosed after this age (designated A1b) can be described as later onset paediatric inflammatory
The Handling Editor for this article was Professor Jonathan Rhodes, and it was accepted for publication after full peer-review. bowel disease (LO-IBD), albeit studies preceding the Paris classification had used a range of ages including <8 and <5 years as the cutoff for early onset disease. 14, 15 Research has only recently begun to address the epidemiology and phenotypic differences in EO-IBD. [14] [15] [16] [17] It is broadly recognised that EO-IBD differs in disease type, location, behaviour, gender preponderance and genetically attributable risk compared with older paediatric inflammatory bowel disease. 14, 18 Current data suggest 4%-15% of all EO-IBD is diagnosed before the age of 5 years, although national population-based data describing the incidence and outcomes of EO-IBD are limited. 17 The complex interplay of genetic, environmental, microbial and host immune factors differ between those with paediatric inflammatory bowel disease and adult-onset disease. [19] [20] [21] While between 25% and 30% of patients are noted to have a positive family history of inflammatory bowel disease, 13, 22 those with an affected first degree relative tend to have an earlier onset and increased disease severity compared to their affected relative. [23] [24] [25] The greater relative contributions of host genetic and immune responses in paediatric inflammatory bowel disease may account in part for the differences in phenotype and behaviour between childhood-and adult-onset inflammatory bowel disease. 14, 18, [26] [27] [28] [29] Panenteric disease and early disease extension are more common features of paediatric inflammatory bowel disease, although patients <8 years of age are more likely to have isolated colonic disease and less ileal involvement. 8, 14, 15, 18, [29] [30] [31] [32] Clinical outcomes differ between childhood-and adult-onset IBD with higher rates of immunosuppressant therapy use, higher 2-year colectomy rates in paediatric UC and lower 2-year surgery rates in paediatric CD. 18, 26, 29, 31 Previous studies of EO-IBD have primarily relied on the analysis of single and/or tertiary centre patient cohort data. Regional studies using health administrative data are limited in their ability to detail the clinical phenotypes and course of IBD. National cohort studies of epidemiology and clinical outcomes are often drawn from multiple participating centres with potential for ascertainment bias or loss of data fidelity between centres. Ireland is uniquely placed among Western European countries, as it has just a single paediatric gastroenterology centre serving the entire country. The aims of this study were to determine the incidence and phenotype of early onset paediatric inflammatory bowel disease in a national cohort of Irish patients and to compare their outcomes to children with later onset paediatric inflammatory bowel disease.
| MATERIALS AND METHODS
Ireland's National Centre for Paediatric Gastroenterology is based at 
| Statistical analysis
Data were analysed using the Statistical Package for the Social Sciences (SPSS version 17; Chicago, IL, USA). All data were log transformed prior to analysis and a P≤.05 was considered statistically significant. Decimal age was calculated for age of diagnosis. Weight and height z-scores were calculated using the LMSgrowth © Excel add-in programme (Harlow Printing Ltd, Newcastle, UK) and referenced against current UK90 growth reference data. 37 Growth impairment was defined as a height z-score <À1 at 1 year or a decrease in z-score of 0.75 over the first year succeeding diagnosis.
Independent categorical variables were compared using Chi-squared analysis and both independent sample t tests and one-way analysis of variance were used to compare continuous variables. 38 The incidence of CD, UC and IBDU was determined by age and gender distribution. Annual incidence rates were calculated per 100 000 per year, with a confidence interval of 95%. Linear regression analysis was used to examine trends in incidence rates of paediatric inflammatory bowel disease over time. In addition, trends in the incidence of CD and UC were also examined separately using linear regression.
Predictors for disease progression and treatment outcomes including surgery, immunomodulator and biologic use were examined using multivariate conditional logistic regression models.
3 | RESULTS
| Demographics
Between 1 The demographic data of early onset IBD are summarised in Table 3 . All children were Celtic Caucasians. Forty three children (23%) had a weight z-score ≤À1 while 19 (10%) had a height z-score ≤À1. Patients with EO-CD were found to have significantly lower weight z-scores at diagnosis compared to patients with EO-UC (P<.005). A first degree family history of IBD was noted in 15% of patients. No correlation was observed between family history and age of diagnosis (P=.4). Rectal bleeding was their most common presenting feature (66%), followed by diarrhoea (58%), abdominal pain (53%) and weight loss (34%). A small number of extraintestinal manifestations were observed at diagnosis; large joint arthritis (n=1), erythema nodosum (n=6), sclerosing cholangitis (n=5), pancreatitis (n=1) and arthralgia (n=4).
| Incidence rates
A total of 190 cases of EO-IBD were identified over the 15-year study period. 100 000 per year across the study period ( Figure 1 ). There was a significant increase in the incidence of EO-UC (by 0.06/100 000/ year; P=.02) but not EO-CD over the study period (by 0.009/ 100 000/year; P=.739).
| Phenotypes
Disease phenotypes and activity indices for early-and later onset IBD groups are summarised in Table 4 . All (n=92) early onset CD patients were classifiable using the Paris classification. Significantly more males than females had extensive disease (L3AEL4; 31% vs 11%; P=.05) and upper GI disease (L4a; 48% vs 21%; P=.007). Males also had a more severe PCDAI score at diagnosis (52% vs 31%;
P=.05) and were more likely to be commenced on immunomodulators in the first year post-diagnosis (58% vs 31%; P=.02). The overall incidence of perianal disease was similar in early-and later onset IBD patients (24% and 22% respectively). Four patients presented with oral CD only. Those with early onset CD had significantly more isolated colonic disease (L2; 27% vs 17%; P=.01) and significantly less ileocolonic disease (L3; 10% vs 20%; P<.001) compared with later onset CD patients. There were no significant gender differences in the location or behaviour of early onset UC. Although pancolitis (E4) was significantly more prevalent in early-than later onset IBD (71% vs 25%; P=.01), severe disease (S1) was significantly more prevalent at diagnosis in later onset UC (31% vs 16%; P=.01). Ulcerative proctitis was not observed in children under 8 years in this cohort.
| IBD unclassified
Twenty-one patients (11%) presented with early onset IBDU, of whom five (24%) were male. Median age of IBDU diagnosis was an outcome which remained consistent when both UC (P<.001) and CD (P<.001) were examined separately. Significantly more later-
T A B L E 3 Demographic characteristics of early onset and later onset paediatric inflammatory bowel disease
Paediatric IBD CD UC
EO-IBD n=190 LO-PIBD n=298 EO-CD n=92 LO-CD n=157 EO-UC n=77 EO-UC n=124
Male n (%) particularly those with CD (66% vs 47%, P=.007). One-year surgical rates were comparably low in both patient groups (11% and 7%, P=.2).
| Long-term follow-up data
One hundred and nineteen children (63%) with EO-IBD had greater than 3-year long-term follow-up data available. Mean follow-up was P=.07) ( Table 5 ). Immunomodulator use was higher in those diagnosed after 2009 (38% vs 29%; P=.01), while surgical rates were lower in this era (3% vs 15%; P=.01). 
| Diagnosis under 6 years

| DISCUSSION
This is the first national population-based study to specifically describe the epidemiology, phenotypes and clinical outcomes of early onset IBD, using both retrospective and prospective data. We demonstrate that a significant rise in UC, rather than CD, underlies the current rising incidence of early onset IBD in Ireland. As Ireland has a single paediatric gastroenterology centre, ascertainment bias is not a potential confounding factor, and loss-to-follow-up is minimal.
Our incidence rates and trends are in line with recently reported global trends. [1] [2] [3] [4] [5] [6] Benchimol et al. (2009) reported a 5% rise in IBD incidence in children aged 6 months to 4 years, and a 7% rise in those age 5-9 years in Canada. 5 Data from Scotland, also documented a significant increase in IBD in 6-10 year olds. 3 Our study supports the findings of a recent Italian study which also reported a higher incidence of UC in those less than 11 years of age and an increasing incidence of CD with age. 17 Our study revealed a number of novel clinically relevant genderrelated differences in early onset IBD phenotypes and outcomes.
Males, especially those with early onset CD, had more extensive, severe and complex disease phenotypes at diagnosis than females.
Their need for immunomodulator therapy was also higher by 1 year.
Of patients with disease extension/progression over time (n=14), all were male. Our data provide evidence to consider male gender as an independent risk factor for more severe early onset CD, and the associated with the use of immunomodulators at 1 year. 39 Interestingly, they also reported that initial PUCAI was not indicative of future immunomodulator use. Our colectomy rate in early onset UC is similar to recent Italian data, but as biologics rather than surgery are increasingly used as rescue therapy in steroid refractory disease, surgical rates may continue to decline in coming years. 17, 40 The contrasts between early onset and later onset paediatric IBD revealed in this study support the justification for their phenotype sub-classification. We reaffirmed the higher incidence of isolated colonic CD in early onset disease, and that ileocolonic disease increases with age. 14, 17, 18, 29, 30 Given the increased incidence of complex disease behaviour, perianal disease and disease extension over time in early-compared to later onset IBD, it is perhaps not surprising that early onset patients had significantly more relapses than later onset patients in their first year post-diagnosis. A similar study of early onset IBD by Oliva-Hemker et al. (2015) involving 655 children also described a more aggressive disease phenotype over time. 41 However, whether this reflects inherent disease characteristics, more conservative immunomodulator and biologic use in younger patients, or the effects of using immunomodulators or biologics earlier in the disease course of later onset IBD patients warrants further study. Recent data suggest that institution of biologics, but not thiopurine immunomodulators, within 3 months of paediatric CD diagnosis markedly increases 1-year remission and reduces disease complication rates. 42 Throughout this study, we endeavoured to mitigate the potential limitations involved in our study design. While patients were not treated on a strict 'per-protocol' basis, they were treated by a very limited number of senior clinicians. Two independent researchers analysed all charts and collected data, but any discrepancies or conflicting data were discussed and clarified with the lead investigator. 'era effect' of treatments and outcomes for this patient sub-group.
While it is likely, given the evolving treatment literature of the time, that the primary focus of this study was not on later onset disease, but rather early onset IBD.
As it is ethically and clinically difficult to justify routine serial endoscopic reassessments of disease in children, disease location was assumed to be stable and hence disease extension may be underestimated. Finally, only limited-time follow-up outcome data were available, which may have weakened the statistical significance of certain outcomes, such as the need for surgical resection, particularly in those with stricturing or penetrating disease. This may, however, also reflect the effect of biologic therapies on the natural history of disease.
| CONCLUSION S
This population-based, national cohort study of EO-IBD affirms the continuous rise in the incidence of EO-IBD, especially UC, and identifies males as being at particular risk of complex disease phenotypes and clinical outcomes. Sufficient differences exist between early onset and late onset PIBD to warrant separate consideration in future studies of prognostic factors and therapeutic intervention.
Given the relative rarity of EO-IBD in the general population, international multicentre collaborative studies are necessary to fully elucidate its multifactorial aetiology and optimal treatment strategies.
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